System for the production of autologus platelet gel useful for the delivery of medicinal and genetic agents

Abstract

A system for the production of a blood component composition is provided. The system includes a centrifuge having a blood reservoir for receiving and separating a blood sample into multiple components; a dispenser disposed outside of the centrifuge having a first collection chamber containing an activation agent and a second collection chamber containing one or more medicinal agents; means for removing a first portion at least one separated blood component from the centrifuge to the first container and a second portion to the second collection chamber, wherein the first collection chamber activates the first portion and stores the resulting clot and thrombin; a filter for separating the thrombin from the clot; and a nozzle for entraining and mixing the thrombin with the second portion containing the one or more medicinal components.

Description

CROSS-REFERENCED TO RELATED APPLICATIONS[0001]This application is a Continuation application of U.S. patent application Ser. No. 09 / 832,517, filed Apr. 9, 2001, which is a Continuation-in-Part of U.S. patent application Ser. No. 09 / 063,338, filed Apr. 20, 1998, now issued as U.S. Pat. No. 6,444,228, which is a Continuation-in-Part of U.S. patent application Ser. No. 08 / 640,278, filed Apr. 30, 1996, now abandoned. The disclosure of each of the above patent applications is specifically incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]This invention relates to novel methods, devices and apparatuses for the centrifugal separation of a liquid into its components of varying specific gravities, and is more particularly directed toward a blood separation device useful, for example, in the separation of blood components for use in various therapeutic regimens.[0004]2. Description of the State of Art[0005]Centrifugation utilizes ...

AI Technical Summary

Benefits of technology

[0051]Another aspect of this invention provides a portable centrifuge containing a disposable centrifuge bag that maximizes the amount of a predetermined blood fraction that can be harvested from an aliquot of blood that is of greater volume than the capacity of the disposable centrifuge bag.

[0056]Yet another embodiment of the present invention is an apparatus and method for separating components contained in a fluid medium. More particularly, the present invention utilizes the principles of centrifugation to allow for the separation of whole blood into fractions such as platelet rich plasma and platelet poor plasma. In one aspect of the present invention, the above-described separation of the components is provided by utilizing a rotatable centrifuge motor comprising a base having a central column and a disposable centrifuge bag having a central core and which is positionable within the centrifuge motor and rotatable therewith. The disposable centrifuge bag, which holds the whole blood during centrifugation, further comprises an inlet tube for introducing the whole blood to the centrifuge bag, and an outlet tube for removing the desired blood fraction from the centrifuge bag. The inlet and outlet tubes are in fluid communication with a dual lumen tubing. The centrifuge bag is removably fixed within the centrifuge rotor by inserting the raised column through the bag center core and securing with the cover. During the rotation of the centrifuge, components of the whole blood will assume a radial, horizontal position within the centrifuge bag based upon a density of such components, and thus the fluid medium components will be separated from other components having different densities.

[0064]This invention further provides a centrifuge having an internal lead drive mechanism allowing for a compact size.

[0067]This invention further provides an autologous platelet gel wherein the risks associated with the use of bovine and recombinant human thrombin are eliminated.

Problems solved by technology

Discontinuous-flow systems have the advantage that the rotors are relatively small in diameter but have the disadvantage that the extracorporeal volume (i.e., the amount of blood that is out of the donor at any given time during the process) is large.

This, in turn, makes it difficult or impossible to use discontinuous systems on people whose size and weight will not permit the drawing of the amount of blood required to fill the rotor.

Because the bowls in these systems are rigid and have a fixed volume, however, it is difficult to control the hematocrit of the final product, particularly if the amount of blood salvaged is insufficient to fill the bowl with red blood cells.

The McMannis, et al., system takes up a fairly large amount of space, and its flexible pancake-shaped rotor is awkward to handle.

The McMannis, et al., system does not permit the fluid medium to flow into and out of the processing bag at the same time, nor does it permit fluid medium to be pulled out of the processing bag by suction.

Although continuous-flow systems have the advantage that the amount of blood that must be outside the donor or patient can be relatively small, they have the disadvantage that the diameter of the rotor is large.

These systems are as a consequence, large.

Furthermore, they are complicated to set up and use.

One drawback present in the above-described continuous-flow systems has been their use of a rotating seal or coupling element between that portion of the system carried by the centrifuge rotor and that portion of the system which remains stationary.

While such rotating seals have provided generally satisfactory performance, they have been expensive to manufacture and have unnecessarily added to the cost of the flow systems.

Furthermore, such rotating seals introduce an additional component into the system which if defective can cause contamination of the blood being processed.

The continuous-flow systems described above are large and expensive units that are not intended to be portable.

Further, they are also an order of magnitude more expensive than a standard, multi-container blood collection set.

Nevertheless, the whole process remains laborious and requires the separation to occur within a certain time frame to guarantee the quality of the blood components.

This complicates the logistics, especially considering that most blood donations are performed in decentralized locations where no batch processing capabilities exist.

However, the complexity and costs of haemapheresis systems preclude their use by transfusion centers for routine whole blood collection.

The bag comprises a single inlet / outlet tubing for the introduction and removal of fluids to the bag, and consequently cannot be used in a continual, on-line process.

Moreover, the processing bag has a the disadvantage of having 650 milliliter, capacity, which makes the McMannis, et al., device difficult to use as a blood processing device.

Despite the effectiveness and successful use of fibrin glue by medical practitioners in Europe, neither fibrin glue nor its essential components fibrinogen and thrombin are widely used in the United States.

In addition, the more recent appearance of other lipid-enveloped viruses such as HIV, associated with AIDS, cytomegalovirus (CMV), as well as Epstein-Barr virus and the herpes simplex viruses in fibrinogen preparations makes it unlikely that there will be a change in this policy in the foreseeable future.

The above patents by Rose, et al. and Marx, and the technical paper by Berruyer, et al. each disclose methods for preparing fibrin sealants; however, each of these methods suffer disadvantages associated with the use of bovine thrombin as the activating agent.

A serious and life threatening consequence associated with the use of fibrin glues comprising bovine thrombin is that patients have been reported to have a bleeding diathesis after receiving topical bovine thrombin.

This complication occurs when patients develop antibodies to the bovine factor V in the relatively impure bovine thrombin preparations.

These antibodies cross-react with human factor V, thereby causing a factor V deficiency that can be sufficiently severe to induce bleeding and even death.

A further disadvantage associated with the methods disclosed by Marx and Rose, et al. is that the cryoprecipitate preparations require a large amount of time and monetary commitment to prepare.

A further disadvantage associated with the methods previously disclosed is that while human thrombin is contemplated for use as an activator, human thrombin is not available for clinical use and there is no evidence that patients will not have an antigenic response to human thrombin.

A second difficulty with thrombin is that it is autocatalytic, that is, it tends to self-destruct, making handling and prolonged storage a problem.

Images